Fibromyalgia

Gut microbiota-based treatment relieved pain for patients with fibromyalgia.

Of 1156 participants with chronic musculoskeletal pain, 1073 participants retired at an earlier age. Participants with chronic pain were 1.25 times more likely to stop working.

Aquatic therapy for women with fibromyalgia in Spain is better than land-based therapy for reducing pain levels and improving sleep quality, as seen at the 6-week follow-up.

The overall effect of psychological interventions on patients with fibromyalgia was -0.31 for depressive symptoms and -0.15 for anxiety symptoms, which were deemed statistically significant.

The rheumatology month in review highlights cognitive dysfunction in patients with fibromyalgia, explores the impact of obesity on treatment response in rheumatoid arthritis, and evaluates work-related challenges faced by patients with psoriatic arthritis.

A progressive and significant increase in the frequency of strong opioid consumers was observed over a 12-year period, increasing from 5.8% to 12.8%.

Patients with fibromyalgia and cognitive dysfunction report feeling a loss of identify and impaired social interaction.

Fibromyalgia poses challenges extending beyond physical symptoms due to societal misconceptions and inadequate understanding. Clinicians emphasize the importance of addressing mental health, engaging patients actively, and creating supportive environments to improve the wellbeing of these patients.

Patients with fibromyalgia have poorer accuracy for divided attention, mediated by sleep disturbance, according to a new study.

The rheumatology month in review highlights the challenges of fibromyalgia management and uncovers compelling associations regarding rheumatic disease and comorbidities.

The presence of mental health, pain-related illnesses, and metabolic diseases were significantly associated with the worsening of arthritis-related pain, severity, and disease activity.

Findings shed light on the potential significance of recognizing and managing type D personality traits in the context of fibromyalgia care.

Thematic analysis revealed common themes, including uncertainty about the cause of fibromyalgia, feelings of invisibility, confusion about symptoms and flares, and a strong desire for more accessible treatment information.

Only 10% of providers surveyed follow the American College of Rheumatology criteria for fibromyalgia.

Results indicate the potential relevance of pressure pain thresholds for understanding the mechanisms that contribute to pain in fibromyalgia.

The rheumatology month in review highlights fibromyalgia complexities, lupus advancements, and dietary links to gout for improved management.

Among the fibromyalgia studies conducted in the US and Canada over the past 22 years, 90% of participants identified as White.

Approximately one third of patients with temporomandibular disorders had comorbid fibromyalgia.

Results of a database search reveal the management of pain symptoms remains a continued source of frustration and an unmet need for patients with fibromyalgia.

In the November 2023 rheumatology month in review, our editorial team highlights ACR conference coverage, the latest updates in fibromyalgia, and advancements in patient care.

At 12 weeks, significantly more patients with fibromyalgia receiving the smartphone-based intervention reported clinical improvements compared with the control group.

Findings may be related to a variety of influences including a slower life pace during the pandemic and resilience to prolonged stressors.

In a new study, decreased plasma EGR1 protein levels and patients with fibromyalgia had a statistically significant relationship.

Resilience of participants with fibromyalgia had a stronger protective association among participants with average null or mild pain than with moderate or severe pain.

Common themes included preferring a standard list of symptoms, active training programs, and the desire for community.

Patients with juvenile onset fibromyalgia and joint hypermobility demonstrated poorer overall functioning compared with those without joint hypermobility.

Dr Daniel J. Clauw provides an overview of pharmacologic and nonpharmacologic therapeutic approaches for the management of fibromyalgia and comments on challenges and unmet needs for patients.

Daniel J. Clauw, MD, describes the role the brain and CNS play in controlling the setting of nociplastic pain in patients with fibromyalgia and highlights increased patient sensitivity to sensory stimuli.

A clinically significant percentage of patients with fibromyalgia in the immediate intervention group had greater improvements in quality of life compared with patients in the delayed cohort.

Fibromyalgia was 3 times more common among patients with rheumatoid arthritis and Long COVID.